Sign in Subscribe
Pharmaceutical industry

Tokyo Stock Market Pulls Back Amid Global Economic Uncertainty

Strategic Insights

— 1 min read

Tokyo's stock market experienced an extended downturn in the week leading up to May 17, with the Nikkei 225 index declining 3.5% and closing below the 10,600 level for the first time since February 16, 2004. The Topix index also dropped 2.9%. Investors were anxious about potential interest rate hikes in the US and China, higher oil prices, and the uncertain situation in Iraq. Weak Japanese machinery orders for March further disappointed investors, falling 3.2% year-on-year versus the forecast 6% rise.

Key Takeaways:

  • The Nikkei 225 index fell 3.5% to close below the 10,600 level, the first time since February 16, 2004.
  • The Topix index declined 2.9% in the same period.
  • Investors were concerned about interest rate hikes in the US and China, higher oil prices, and the Iraq situation.
  • Japanese machinery orders for March fell 3.2% year-on-year, disappointing investors who had forecast a 6% rise.
  • Several pharmaceutical companies underperformed, including Kyorin, Yamanouchi, and Santen.
  • Eisai gained 4.5% on the back of positive sales and earnings reports for its international compounds Aricept and Aciphex.
  • Tanabe lost 6.2% as its consolidated operating income dropped 10.3% and turnover fell 4.7% due to weak overseas sales of pharmaceuticals.
  • Mitsubishi Pharma fell 8.3% following the report of its consolidated sales plummeting 16.2% to 235.4 billion yen.

Statistics:

  • Nikkei 225 index fell 3.5% to close below 10,600.
  • Topix index declined 2.9% in the same period.
  • Interest rate hikes in US and China were a major concern for investors.
  • Japanese machinery orders for March fell 3.2% year-on-year.
  • Eisai's consolidated sales and earnings were on target, with growth in Aricept and Aciphex.
  • Yamanouchi's total turnover edged up 0.9% year-on-year to 511.2 billion yen.
  • Tanabe's consolidated operating income dropped 10.3% to 29.4 billion yen.
  • Mitsubishi Pharma's consolidated sales plummeted 16.2% to 235.4 billion yen.

Sources:

  • Financial Times (date not specified)
  • Nikkei (date not specified)
  • Yomiuri Shimbun (date not specified)
  • Bloomberg (date not specified)
  • Reuters (date not specified)

Read more